Home > Insider Trading > Filing (0001441844-11-000028)

Filing Details

Accession Number:: 0001441844-11-000028
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-07-06 18:55:59
Reporting Period:: 2011-07-01

Filing Date:: 2011-07-06
Accepted Time:: 2011-07-06 18:55:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
835887	Progenics Pharmaceuticals Inc	PGNX	Pharmaceutical Preparations (2834)	133379479

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1250274	J Robert Israel	777 Old Saw Mill River Road Tarrytown NY 10591	Senior Vp Medical Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-07-01	1,000	$5.33	37,151	No	4	M	Direct
Common Stock	Disposition	2011-07-01	1,000	$7.21	36,151	No	4	S	Direct
Common Stock	Acquisiton	2011-07-01	8,322	$5.46	44,773	No	4	M	Direct
Common Stock	Disposition	2011-07-01	6,930	$7.40	37,843	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	ESPP (right to buy)	Disposition	2011-07-01	8,322	$0.00	8,322	$5.46
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-07-01	1,000	$0.00	1,000	$5.33
Common Stock	Non-Qualified Stock Option (right to buy)	Acquisiton	2011-07-01	70,000	$0.00	70,000	$7.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2011-07-01	2011-07-01	No	4	M	Direct
37,000	2010-07-01	2019-07-01	No	4	M	Direct
70,000	2012-07-01	2021-07-01	No	4	A	Direct

Footnotes

The Reporting Person is exercising options under this grant in pre-established increments under and in accordance with provisions of a previously established Plan of Sale under Rule 10b5-1, which was established in accordance with the policies and procedures of the Issuer.
This transaction was executed in multiple trades at prices ranging from $7.02 to $7.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Acquired upon the complete exercise of a grant under the Non-Qualified Employee Stock Purchase Plan, which grant was previously reported at the start of a six month option term, to acquire common stock up to an option amount which is 25% of the optionee's quarterly salary less $6,250, at a purchase price equal to the lower of 100% of the market value on the date of grant or 85% of the market value on the date of exercise.
Includes shares of common stock acquired from the non-reportable exercise of a Grant under the Qualified Employee Stock Purchase Plan.
Granted under the Company's Non-Qualified Employeee Stock Purchase Plan.
The option was granted on the first day of the option term and previously reported as a right to purchase shares of the Company's common stock at an exercise price equal to the market value on the date of grant. In accordance with the Non-Qualified Employee Stock Purchase Plan, the option is ultimately exercisable for an exercise price which is the lower of 100% of the market value on the grant date or 85% of the market value on the exercise date. The number of shares acquired upon exercise is based on the option amount divided by the lower of 100% of the market value on the grant date or 85% of the market value on the exercise date.
The stock options become exercisable in three equal annual installments, commencing one year from the grant date.